A study to test GlaxoSmithKline’s (GSK) Herpes Zoster (HZ) subunit vaccine’s long-term immune response in previously vaccinated kidney transplant adults and then to test if 2 additional doses of the vaccine are safe and able to generate an immune response

Trial Identifier: 212340
Sponsor: GlaxoSmithKline
Start Date: December 2019
Primary Completion Date: August 2022
Study Completion Date: June 2024
Condition: Other - Conditions

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
BELGIUM Brussel, BELGIUM, 1090
CANADA, ON Toronto, ON, CANADA, M5B 1W8
CANADA, ON Toronto, ON, CANADA, M5G 2N2
FINLAND Helsinki, FINLAND, 00029
KOREA,_REPUBLIC_OF Seoul, KOREA,_REPUBLIC_OF, 06351
KOREA,_REPUBLIC_OF Seoul, KOREA,_REPUBLIC_OF, 137-701
PANAMA Panama City, PANAMA, 1001
SPAIN Barcelona, SPAIN, 08035
SPAIN Barcelona, SPAIN, 08036
SPAIN Barcelona, SPAIN, 08907
SPAIN Madrid, SPAIN, 28040
SPAIN Madrid, SPAIN, 28034
SPAIN Santander, SPAIN, 39008
SPAIN Sevilla, SPAIN, 41013
TAIWAN,_PROVINCE_OF_CHINA Tau-Yuan, TAIWAN,_PROVINCE_OF_CHINA, 333